Aethlon medical reaches key milestone with enrollment of the first patient in (fpi) its hemopurifier® cancer trial in australia

Patient enrolled at the cancer clinical trial unit, calhn, royal adelaide hospital aethlon's trial is a safety, feasibility, and dose finding study of the hemopurifier® in patients with solid tumors not responding to anti-pd-1 antibodies san diego , nov. 11, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its australian safety, feasibility and dose-finding clinical trial of the hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® (pembrolizumab) or opdivo® (nivolumab) (aemd-2022-06 hemopurifier study). the patient was enrolled on october 29, 2024, by prof.
AEMD Ratings Summary
AEMD Quant Ranking